PMID- 28827830
OWN - NLM
STAT- MEDLINE
DCOM- 20171013
LR  - 20240326
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 8
DP  - 2017
TI  - Treatment effects between monotherapy of donepezil versus combination with 
      memantine for Alzheimer disease: A meta-analysis.
PG  - e0183586
LID - 10.1371/journal.pone.0183586 [doi]
LID - e0183586
AB  - BACKGROUND: This is the first meta-analysis to compare the treatment effects and 
      safety of administering donepezil alone versus a combination of memantine and 
      donepezil to treat patients with moderate to severe Alzheimer Disease, 
      particularly regarding cognitive functions, behavioral and psychological symptoms 
      in dementia (BPSD), and global functions. METHODS: PubMed, Medline, Embase, 
      PsycINFO, and Cochrane databases were used to search for English and non-English 
      articles for inclusion in the meta-analysis to evaluate the effect size and 
      incidence of adverse drug reactions of different treatments. RESULTS: Compared 
      with patients who received donepezil alone, those who received donepezil in 
      combination with memantine exhibited limited improvements in cognitive functions 
      (g = 0.378, p < .001), BPSD (g = -0.878, p < .001) and global functions (g = 
      -0.585, p = .004). Gradual titration of memantine plus a fixed dose and gradual 
      titration of donepezil as well as a fixed dose and gradual titration of memantine 
      resulted in limited improvements in cognitive functions(g = 0.371, p = .005), 
      BPSD(g = -0.913, p = .001), and global functions(g = -0.371, p = .001). 
      CONCLUSION: Both in the 24th week and at the final evaluation point, the 
      combination of donepezil and memantine led to greater improvement in cognitive 
      functions, BPSD, and global functions than did donepezil alone in patients with 
      moderate to severe Alzheimer Disease.
FAU - Chen, Ruey
AU  - Chen R
AD  - School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
FAU - Chan, Pi-Tuan
AU  - Chan PT
AD  - Department of Nursing, En Chu Kong Hospital, Taipei, Taiwan.
FAU - Chu, Hsin
AU  - Chu H
AD  - Aviation Physiology Research Laboratory, Kaohsiung Armed Forces General Hospital 
      Gangshan Branch, Kaohsiung, Taiwan.
AD  - Institute of Aerospace and Undersea Medicine, School of Medicine, National 
      Defense Medical Center, Taipei, Taiwan.
AD  - Department of Neurology, Tri-Service General Hospital, National Defense Medical 
      Center, Taipei, Taiwan.
FAU - Lin, Yu-Cih
AU  - Lin YC
AD  - School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
AD  - Department of Anesthesiology, Taipei Medical University Hospital, Taipei, Taiwan.
FAU - Chang, Pi-Chen
AU  - Chang PC
AD  - School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
FAU - Chen, Chien-Yu
AU  - Chen CY
AD  - Department of Anesthesiology, Taipei Medical University Hospital, Taipei, Taiwan.
AD  - Department of Anesthesiology, School of Medicine, College of Medicine, Taipei 
      Medical University, Taipei, Taiwan.
AD  - Graduate Institute of Humanities in Medicine, Taipei Medical University, Taipei, 
      Taiwan.
FAU - Chou, Kuei-Ru
AU  - Chou KR
AUID- ORCID: 0000-0002-4882-3503
AD  - School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
AD  - Department of Nursing, Taipei Medical University-Shuang Ho Hospital, Taipei, 
      Taiwan.
AD  - Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20170821
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Indans)
RN  - 0 (Nootropic Agents)
RN  - 0 (Piperidines)
RN  - 8SSC91326P (Donepezil)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Alzheimer Disease/*drug therapy
MH  - Donepezil
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Indans/administration & dosage/*therapeutic use
MH  - Memantine/administration & dosage/*therapeutic use
MH  - Nootropic Agents/administration & dosage/*therapeutic use
MH  - Piperidines/administration & dosage/*therapeutic use
PMC - PMC5565113
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2017/08/23 06:00
MHDA- 2017/10/14 06:00
PMCR- 2017/08/21
CRDT- 2017/08/23 06:00
PHST- 2017/01/24 00:00 [received]
PHST- 2017/08/07 00:00 [accepted]
PHST- 2017/08/23 06:00 [entrez]
PHST- 2017/08/23 06:00 [pubmed]
PHST- 2017/10/14 06:00 [medline]
PHST- 2017/08/21 00:00 [pmc-release]
AID - PONE-D-17-02291 [pii]
AID - 10.1371/journal.pone.0183586 [doi]
PST - epublish
SO  - PLoS One. 2017 Aug 21;12(8):e0183586. doi: 10.1371/journal.pone.0183586. 
      eCollection 2017.